When Three Medications Aren’t Enough: A New Hope for Resistant Hypertension

Sponsored by E-Star BioTech

This partnership between E-Star BioTech and BlackDoctor’s Clinical Trial Resource Center aims to educate and encourage clinical trial participation by informing potential subjects of the BOLD-HTN trial, which focuses on resistant hypertension among African Americans.

Treatment with MANP 

MANP (modified Atrial Natriuretic Peptide) is a natriuretic peptide, or hormone, developed at the Mayo Clinic for the treatment of resistant hypertension.¹ MANP has not been approved in the US, however, the FDA has permitted its use in this research study (NCT06343298).

Benefits of MANP

Previous trials have demonstrated that MANP is safe and well tolerated with no serious adverse events. It has been especially effective in the African American participants, who experienced greater reductions in SBP compared to non-African American participants, particularly at higher doses. 

Purpose of the Research Study

This research study (NCT06343298) aims to evaluate the safety and biological effects of MANP in lowering blood pressure in individuals with resistant hypertension, focusing specifically on the African American population. If you are an adult aged 18 to 80 and currently take three or more medications for resistant hypertension, you may qualify to participate.

Participation in the study will last up to 12 weeks. During this time, MANP will be administered daily as a subcutaneous (under the skin) injection for 6 weeks. Participants will be randomly assigned (like flipping a coin) to receive either the study drug or a placebo (an inactive substance) for 42 consecutive days, with a 50% chance of being in either group. You cannot choose your group.

If you are in the group receiving MANP, the dose will gradually increase (a process called titration) until the highest effective dose is reached. Neither you, the study doctor, nor the research team will know whether you are receiving MANP or the placebo, although this information can be accessed in case of an emergency.

Participation in the Research Study

Participation in this research is entirely voluntary. It is crucial to be open and honest with the study doctor about your health history and medical conditions to ensure your safety throughout the study.

1. McKie PM, Ichiki T, Burnett JC Jr.; M-atrial natriuretic peptide: a novel antihypertensive protein therapy. Curr Hypertens Rep. 2012 Feb;14(1):62-9.

Learn more about a clinical trial for Resistant Hypertension.